C.ZhangY.SwrdK.BensonM.UddmanR.et al (2002)
Combination with Metformin or Metformin with SGLT-2 Inhibitors In a 26-week, double-blind, double-dummy trial (Trial 4, NCT02863419), 711 adult patients with type 2 diabetes mellitus on metformin alone or metformin with SGLT-2 inhibitors were randomized to RYBELSUS 14 mg once daily, liraglutide 1.8 mg subcutaneous injection once daily or placebo
This article explores current clinical recommendations, surgical considerations, and safety factors to help patients and healthcare professionals determine the optimal timing for resuming GLP-1 therapy following surgical procedures
Animal reproduction studies have shown fetal harm, including structural abnormalities and growth alterations, though human data remain limited
PeerJ 4, e2584
While constipation is a common side effect, Bowel Obstruction or Ileus (where the gut stops moving entirely) is a rare but serious medical emergency associated with GLP-1 use